Curevac Nv Stock Alpha and Beta Analysis

CVAC Stock  USD 2.56  0.07  2.81%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CureVac NV. It also helps investors analyze the systematic and unsystematic risks associated with investing in CureVac NV over a specified time horizon. Remember, high CureVac NV's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CureVac NV's market risk premium analysis include:
Beta
1.11
Alpha
(0.45)
Risk
3.13
Sharpe Ratio
(0.12)
Expected Return
(0.39)
Please note that although CureVac NV alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, CureVac NV did 0.45  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of CureVac NV stock's relative risk over its benchmark. CureVac NV has a beta of 1.11  . CureVac NV returns are very sensitive to returns on the market. As the market goes up or down, CureVac NV is expected to follow. As of November 22, 2024, Book Value Per Share is expected to decline to 1.90. In addition to that, Tangible Book Value Per Share is expected to decline to 1.82.

Enterprise Value

454.86 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out CureVac NV Backtesting, CureVac NV Valuation, CureVac NV Correlation, CureVac NV Hype Analysis, CureVac NV Volatility, CureVac NV History and analyze CureVac NV Performance.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

CureVac NV Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CureVac NV market risk premium is the additional return an investor will receive from holding CureVac NV long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CureVac NV. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CureVac NV's performance over market.
α-0.45   β1.11

CureVac NV expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of CureVac NV's Buy-and-hold return. Our buy-and-hold chart shows how CureVac NV performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

CureVac NV Market Price Analysis

Market price analysis indicators help investors to evaluate how CureVac NV stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CureVac NV shares will generate the highest return on investment. By understating and applying CureVac NV stock market price indicators, traders can identify CureVac NV position entry and exit signals to maximize returns.

CureVac NV Return and Market Media

The median price of CureVac NV for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 2.91 with a coefficient of variation of 7.6. The daily time series for the period is distributed with a sample standard deviation of 0.22, arithmetic mean of 2.95, and mean deviation of 0.18. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
09/09/2024
2
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
09/12/2024
3
CureVac N.V.s Share Price Could Signal Some Risk
09/16/2024
4
Contrasting CureVac and Innovation Pharmaceuticals
10/08/2024
5
CureVac names former Cardior CFO Axel Sven Malkomes as new CFO
11/04/2024
6
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
11/12/2024
7
A white couple donated 80 acres in an act of reparations. Now its becoming a home for Black farmers.
11/14/2024
8
Is the Options Market Predicting a Spike in CureVac Stock
11/20/2024

About CureVac NV Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CureVac or other stocks. Alpha measures the amount that position in CureVac NV has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2021 2022 2023 2024 (projected)
Payables Turnover1.952.72.682.82
Days Of Inventory On Hand86.0647.5972.79132.4

CureVac NV Upcoming Company Events

As portrayed in its financial statements, the presentation of CureVac NV's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CureVac NV's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of CureVac NV's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of CureVac NV. Please utilize our Beneish M Score to check the likelihood of CureVac NV's management manipulating its earnings.
23rd of April 2024
Upcoming Quarterly Report
View
4th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
23rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with CureVac NV

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out CureVac NV Backtesting, CureVac NV Valuation, CureVac NV Correlation, CureVac NV Hype Analysis, CureVac NV Volatility, CureVac NV History and analyze CureVac NV Performance.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
CureVac NV technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of CureVac NV technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of CureVac NV trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...